Nabi scores $540M pact for NicVAX; Kansas University gets vaccine research contract;

> Nabi Biopharmaceuticals has wrapped a licensing deal worth potentially more than $540 million with GlaxoSmithKline for its experimental therapy designed to treat nicotine addiction and prevent smokers who kick the habit from tearing open a fresh pack. Report

The Associated Press details the metoric rise of the vaccine business in recent years, from the days when vaccine research was all but abaondon to the coming golden era of groundbreaking therapies. Report 

The National Institutes of Health's National Institute for Allergy and Infectious Disease has granted Kansas University a five-year, $6.85 million research contract to help study how to boost the effectiveness and safety of infectious disease vaccines. Report

And Finally... Vets are suggesting that some dogs get the H3N8--a horse virus that jumped to canines about five years ago. Report

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.